<SEC-DOCUMENT>0001104659-25-067929.txt : 20250715
<SEC-HEADER>0001104659-25-067929.hdr.sgml : 20250715
<ACCEPTANCE-DATETIME>20250715070059
ACCESSION NUMBER:		0001104659-25-067929
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20250715
FILED AS OF DATE:		20250715
DATE AS OF CHANGE:		20250715

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Adagene Inc.
		CENTRAL INDEX KEY:			0001818838
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39997
		FILM NUMBER:		251123056

	BUSINESS ADDRESS:	
		STREET 1:		4F, BUILDING C14, NO. 218, XINGHU STREET
		STREET 2:		SUZHOU INDUSTRIAL PARK
		CITY:			JIANGSU
		STATE:			F4
		ZIP:			00000
		BUSINESS PHONE:		86-512-87773632

	MAIL ADDRESS:	
		STREET 1:		4F, BUILDING C14, NO. 218, XINGHU STREET
		STREET 2:		SUZHOU INDUSTRIAL PARK
		CITY:			JIANGSU
		STATE:			F4
		ZIP:			00000
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>tm2520965d1_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WASHINGTON, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM&nbsp;6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO
RULE 13a-<BR>
16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For the Month of July 2025</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Commission File Number: 001-39997</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Adagene Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>4F, Building C14, No. 218</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Xinghu Street, Suzhou Industrial Park</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Suzhou, Jiangsu Province, 215123</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>People&rsquo;s Republic of China</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>+86-512-8777-3632</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Address of principal executive offices)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will file annual
reports under cover of Form&nbsp;20-F or Form&nbsp;40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Form&nbsp;20-F&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT>&nbsp;&nbsp;&nbsp;Form&nbsp;40-F&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><B>Adagene Inc.</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 51%">&nbsp;</TD>
    <TD STYLE="width: 6%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 43%">/s/ Peter Luo</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Name:</TD>
    <TD>Peter Luo</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>Chief Executive Officer</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Date: July 15, 2025</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT&nbsp;INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; padding-right: 0pt; padding-left: 0pt; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; width: 8%"><B>Exhibit</B></TD>
    <TD STYLE="padding-bottom: 1pt; white-space: nowrap; width: 2%"><B>&nbsp;</B></TD>
    <TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center; width: 90%"><B>Description</B></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-indent: 0pt"><A HREF="tm2520965d1_ex99-1.htm">99.1</A></TD>
    <TD STYLE="vertical-align: top; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: justify; vertical-align: bottom"><A HREF="tm2520965d1_ex99-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">Press release titled &ldquo;Adagene Announces Regulatory Update on Clinical Development Plan for Muzastotug in Microsatellite Stable Colorectal
Cancer Following Productive Type B (End of Phase 1) Meeting with FDA.&rdquo;</FONT></A></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm2520965d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><IMG SRC="tm2520965d1_ex99-1img001.jpg" ALT="" STYLE="height: 34px; width: 161px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>Adagene Announces
Regulatory Update on Clinical Development Plan for<BR>
Muzastotug in Microsatellite Stable Colorectal Cancer Following<BR>
Productive Type B
(End of Phase 1) Meeting with FDA</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>- Alignment gained on Phase 2 inclusion/exclusion
criteria, primary and secondary endpoints, and study design, including sample size and dosing regimen</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>- Company expects to begin enrolling patients
in Phase 2 in 2H 2025</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SAN DIEGO and SUZHOU, China, July&nbsp;15, 2025
(GLOBE NEWSWIRE) -- Adagene Inc. (&ldquo;Adagene or the Company&rdquo;) (Nasdaq: ADAG), a company transforming the discovery and development
of novel antibody-based therapies, today announced outcomes from its Type B meeting with the United States Food and Drug Administration
(FDA). Adagene has received written feedback from the FDA on its clinical development plan to evaluate muzastotug (ADG126) in combination
with Merck&rsquo;s (known as MSD outside of the US and Canada) anti-PD-1 therapy, KEYTRUDA&reg; (pembrolizumab: 200 mg, Q3W) in patients
with microsatellite stable colorectal cancer (MSS CRC).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ADG126 is a masked, anti-CTLA-4 SAFEbody&reg;
that targets a unique epitope of CTLA-4 in regulatory T cells (Tregs) in the tumor microenvironment. ADG126 is currently in phase 1b/2
clinical studies in combination with anti-PD-1 therapy, particularly focused on MSS CRC. To date, over 150 patients have received ADG126,
either as monotherapy or in combination with anti-PD-1 therapy. Adagene has completed patient enrollment for the MSS CRC dose expansion
cohorts of the ADG126 + pembrolizumab combination (NCT05405595). The phase 2 trial will be conducted primarily to identify which of the
two doses of ADG126 will be used in the phase 3 trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Key Outcomes from the FDA Type B Meeting</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><B>Patient Population:</B> Future trials will enroll late-line patients with MSS CRC without liver metastases,
including those with peritoneal metastasis/involvement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><B>Dose and Regimen</B>: Phase 2 will randomize patients to either 10 mg/kg or 20 mg/kg of ADG126 in combination
with pembrolizumab, using an induction-maintenance regimen, without cycle limitations of ADG126.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><B>Phase 2 Trial Design:</B> Approximately 30 patients will be enrolled in each arm of the Phase 2 study,
without a requirement for an ADG126 monotherapy arm.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><B>Phase 3 Trial Design: </B>The FDA agreed with Adagene&rsquo;s proposed standard-of-care (SOC) control
arm for the Phase 3 clinical trial and confirmed that an ADG126 monotherapy arm is also not required in the pivotal study.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><B>Phase 2 Endpoints:</B> The primary endpoint of the Phase 2 trial will be overall response rate (ORR).
Secondary endpoints include duration of response (DOR), progression-free survival (PFS), and overall survival (OS).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><B>Phase 3 Endpoints: </B>The primary endpoint of the Phase 3 trial will be OS. Secondary endpoints will
include PFS, DOR and ORR.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;Receiving the FDA&rsquo;s endorsement to
explore ADG126 at doses 10 to 20 times higher than other anti-CTLA-4 antibodies, without limitations on treatment cycles, has demonstrated
a nearly two-fold increase in ORR from 17% at 10 mg/kg to 29% at 20 mg/kg, while Grade 3 treatment-related adverse events (TRAEs) remain
approximately 20% at comparable drug exposures for ADG126 at 10 mg/kg Q3W versus 20 mg/kg Q6W. These results highlight the wide therapeutic
index and favorable safety profile we have seen to date in the clinic&rdquo; said Dr.&nbsp;Marwan Fakih, Professor of&nbsp;Medical Oncology
and Therapeutics Research&nbsp;at&nbsp;City of Hope.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Peter Luo, Ph.D., CEO and President of R&amp;D
at&nbsp;Adagene added, &ldquo;Our Phase 1b/2 trial has produced robust dose-dependent efficacy data with a potential best-in-class safety
profile, identifying two optimized dose levels for the Phase 2, consistent with Project Optimus. With the FDA&rsquo;s endorsement to advance
into the Phase 2 part of the clinical trial, we&rsquo;d like to thank our strategic partner, Merck, for supplying pembrolizumab to support
this exciting randomized dose optimization cohort to identify a single dose to take into Phase 3, a critical step towards registrational
trial for FDA approval.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About&nbsp;Adagene</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Adagene Inc.&nbsp;(Nasdaq: ADAG) is a platform-driven,
clinical-stage biotechnology company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies.
Adagene combines computational biology and artificial intelligence to design novel antibodies that address globally unmet patient needs.
The company has forged strategic collaborations with reputable global partners that leverage its SAFEbody<SUP>&reg;</SUP>&nbsp;precision
masking technology in multiple approaches at the vanguard of science.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Powered by its proprietary&nbsp;Dynamic Precision
Library&nbsp;(DPL) platform, composed of NEObody&trade;, SAFEbody, and POWERbody&trade; technologies, Adagene&rsquo;s highly differentiated
pipeline features novel immunotherapy programs. The company&rsquo;s SAFEbody technology is designed to address safety and tolerability
challenges associated with many antibody therapeutics by using precision masking technology to shield the binding domain of the biologic
therapy. Through activation in the tumor microenvironment, this allows for tumor-specific targeting of antibodies in tumor microenvironment,
while minimizing on-target off-tumor toxicity in healthy tissues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Adagene&rsquo;s lead clinical program, ADG126
(muzastotug), is a masked, anti-CTLA-4 SAFEbody that targets a unique epitope of CTLA-4 in regulatory T cells (Tregs) in the tumor microenvironment.
ADG126 is currently in phase 1b/2 clinical studies in combination with anti-PD-1 therapy, particularly focused on Metastatic Microsatellite-stable
(MSS) Colorectal Cancer (CRC). Validated by ongoing clinical research, the SAFEbody platform can be applied to a wide variety of antibody-based
therapeutic modalities, including Fc empowered antibodies, antibody-drug conjugates, and bi/multi-specific T-cell engagers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For more information, please visit:&nbsp;https://investor.adagene.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Follow&nbsp; Adagene&nbsp;on&nbsp;WeChat,&nbsp;LinkedIn&nbsp;and&nbsp;X.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SAFEbody<SUP>&reg;</SUP>&nbsp;is a registered trademark in&nbsp;the&nbsp;United
States, China, Australia, Japan, Singapore, and the&nbsp;European Union.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">KEYTRUDA<SUP>&reg;</SUP>&nbsp;is a registered trademark of&nbsp;Merck
Sharp&nbsp;&amp; Dohme LLC, a subsidiary of&nbsp;Merck&nbsp;&amp; Co.,&nbsp;Inc.,&nbsp;Rahway, NJ, USA</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Safe Harbor Statement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release contains forward-looking statements,
including statements regarding &nbsp;the impact of Sanofi&rsquo;s strategic investment and Adagene&rsquo;s relationship with Sanofi; the
expected timeframe for funding Adagene&rsquo;s operating plan with current cash and cash equivalents and the proceeds from Sanofi&rsquo;s
investment;&nbsp; certain clinical results of ADG126, the potential implications of clinical data for patients, and Adagene&rsquo;s advancement
of, and anticipated preclinical activities, clinical development, regulatory milestones, and commercialization of its product candidates.
Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors,
including but not limited to Adagene&rsquo;s ability to demonstrate the safety and efficacy of its drug candidates; the clinical results
for its drug candidates, which may not support further development or regulatory approval; the content and timing of decisions made by
the relevant regulatory authorities regarding regulatory approval of Adagene&rsquo;s drug candidates; Adagene&rsquo;s ability to achieve
commercial success for its drug candidates, if approved; Adagene&rsquo;s ability to obtain and maintain protection of intellectual property
for its technology and drugs; Adagene&rsquo;s reliance on third parties to conduct drug development, manufacturing and other services;
Adagene&rsquo;s limited operating history and Adagene&rsquo;s ability to obtain additional funding for operations and to complete the
development and commercialization of its drug candidates; Adagene&rsquo;s ability to enter into additional collaboration agreements beyond
its existing strategic partnerships or collaborations, as well as those risks more fully discussed in the &ldquo;Risk Factors&rdquo; section
in Adagene&rsquo;s filings with the&nbsp;U.S. Securities and Exchange Commission. All forward-looking statements are based on information
currently available to&nbsp;Adagene, and&nbsp;Adagene&nbsp;undertakes no obligation to publicly update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise, except as may be required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Investor Contacts:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Raymond Tam</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">raymond_tam@adagene.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Corey Davis</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">LifeSci Advisors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">cdavis@lifesciadvisors.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tm2520965d1_ex99-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2520965d1_ex99-1img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !H >8# 2(  A$! Q$!_\0
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M/^0O:?\ 7#_V8UQ=>I1IP=--H^ S/&8B&+J1A-I)]_)'1?\ "<:__P _:_\
M?I?\*/\ A.-?_P"?M?\ OTO^%:"?#G4'17%Y:X8 _P 7^%._X5OJ/_/[:_\
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M/5[-7SE\0;@W/CS5G)SME$8_X"H7^E=>#C>I?L>;F4W&C9=6<T 68*H+,3@
M=2:^E_">@0^&_#UM8(JB7;OG<#[\AZG^@]@*\#\&V8OO&6D6Y&5-RKD>H7YC
M_*OI>ML;-Z1.?*J:M*H_0****\X]H\^^+>BI>^&5U-4_TBQ<?,.IC8@$?G@_
MG7AM?3WB:QEU/POJ=E F^::V=8US]YL<#GWQ7A?_  KCQ;_T"'_[_1__ !5>
MGA*J4+29X.8T).JI05[H]5^%NI&_\$6\;ON>TD> D^@.5'Y,!^%=I7 _"[0]
M7T"PU&WU2U:W$DJR1 NK9XP>A/H*[ZN&M;VCL>MA7+V,>;>QYK\2/^0O:?\
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M .S5Z#7GWPT_UFI?2/\ ]FKT&N;$_P 1GN9)_N,/G^;/-?B1_P A>T_ZX?\
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MQ&;T983&*M3TOJO7K_7F=3\0"&\2@@Y!MT(/YUSME_Q_VW_75?YBG7E[+?&
MR\M#"L(.>H7./TIME_Q_V_\ UU7^8K:,>6%F>97K*MBG5CLVG^1[O1117BGZ
M>>-^+?\ D:M0_P"N@_\ 013/"_\ R,^G?]=A3_%O_(U:A_UT'_H(IGA?_D9]
M._Z["O8_Y=?+]#\V?_(P_P"W_P#VX]GHHHKQS])"BBB@ HHHH Y?XAZF=+\$
M:C(C8DF00)SCES@_ID_A7SI7K7QHU,8TS25;G+7+C\U7_P!GKR6O7PD;4[]S
MYO,JG-6Y>Q[C\(-.^R^%)KUAAKR<D'U5?E'Z[J]"K*\-:=_97AG3;$@!X;=
M^/[^,M^N:U:\RK+FFV>]0A[.E&/9!11169L>$_%S3OLGC!;I4PEY;JY;U9?E
M/Z!?SKC]'U!M*UFROT/-O,LA]P#R/Q&17KOQCT[S_#]GJ"C+6T^QC_LN/\0O
MYUXK7LX=\]))^A\OC8NGB&UZGUBCK)&KH<JP!!]14-]_R#[G_KDW\C6#\/\
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MPC&M_P#0,N?^^***KZW+L<_^KE#^=_@'_",:W_T#+G_OBC_A&-;_ .@9<_\
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MJ'_",:W_ - RY_[XH_X1C6_^@9<_]\444_K<NQG_ *N4/YW^ ?\ ",:W_P!
MRY_[XH_X1C6_^@9<_P#?%%%'UN78/]7*'\[_  .G\$:/J.GZI<27=G-"C0X#
<.N 3N'%%%%<]2HYRYF>SA,''"TE2B[K_ #/_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
